MENTAL HEALTH

A research update from Japan reports that some high school students experienced lower psychological distress during the COVID-19 pandemic. Researchers examined responses from 84 adolescents in Tokyo and found that changes in school and social environments may have influenced their mental health experiences.

A medical research update reports that certain organic pollutants, including furans, dioxins and related chemical compounds, may be associated with an increased risk of type 2 diabetes. The finding highlights the potential role of environmental exposures in metabolic health.

A 2 November health-news roundup highlights growing concern about online misogyny and manosphere content and their potential effects on young people's wellbeing and society.

A mental health report published on 29 October 2026 examines the difference between normal anxiety and anxiety that may indicate a mental health disorder. Anxiety is a common response to stress, but symptoms that are excessive, persistent, difficult to control, or disruptive to daily life may require professional evaluation.

On 28 October 2026, reports described Eli Lilly's announcement that its experimental medicine retatrutide outperformed semaglutide, the active ingredient in Ozempic, in a Phase III trial involving people with type 2 diabetes. The results have attracted attention because of the continuing search for more effective treatments for diabetes and obesity. Retatrutide remains an investigational medicine, and reported trial findings should not be interpreted as proof that it is approved or suitable for routine treatment.

A health report published on 26 October 2026 highlighted a $20 million research initiative launched by McLean Hospital to investigate metabolic psychiatry. The programme will explore potential connections between metabolic health and mental health, including whether approaches involving ketogenic diets and GLP-1 medicines could have a role in psychiatric care. These approaches remain areas of investigation rather than established replacements for standard treatment.

A health report updated on 26 October 2026 examines whether mindfulness and self-compassion may help ease symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). These approaches may help some women manage stress and emotional distress, but persistent or severe symptoms still require appropriate medical assessment.

AstraZeneca has reported encouraging results for its experimental cancer drug sonesitatug vedotin, also called Sone-Ve, in patients with previously treated advanced stomach and related gastrointestinal cancers. Results presented at the European Society for Medical Oncology Congress on 25 October 2026 showed improved overall survival compared with physician-selected treatments, although progression-free survival results were less conclusive.

A report summarised by the New Hampshire Medical Society on 22 October highlighted evidence that adults with type 1 diabetes are more likely to experience symptoms of depression and anxiety. The findings underline the importance of considering psychological wellbeing alongside glucose management.

Medical Xpress reported on 21 October that University of Sydney researchers identified a possible subtype called “circadian depression” in data from more than 10,000 Australians with severe, recurrent or persistent depression. About one-quarter of participants in the study were classified in this group.

Contemporary Pediatrics reported on 22 October that treatment for paediatric mental-health conditions had risen above pre-pandemic levels, with antidepressant initiation increasing sharply among girls after the COVID-19 pandemic.

Medical Xpress reported on 21 October that Cornell University researchers found that reducing damage to the nuclei of heart muscle cells improved heart function and survival in mice with LMNA-related dilated cardiomyopathy. The findings may help scientists investigate new approaches to inherited heart disease.